Diphtheria toxin fused to variant interleukin-3 provides enhanced binding to the interleukin-3 receptor and more potent leukemia cell cytotoxicity

Tie Fu Liu, Jeffrey O. Urieto, Joseph E. Moore, Mark S. Miller, A. Corinne Lowe, Andrew Thorburn, Arthur E. Frankel

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Chemoresistance is a common cause of treatment failure in patients with acute myeloid leukemia (AML). We generated a diphtheria toxin (DT) fusion protein composed of the catalytic and translocation domains of DT (DT 388) fused to interleukin-3 (IL-3). IL-3 receptors (IL-3R) are overexpressed on blasts from many AML patients. DT388IL-3 showed cytotoxicity to leukemic blasts in vitro and in vivo and minimal damage to normal tissues in nonhuman primate models. However, only a fraction of patient leukemic samples were sensitive to the agent. To enhance the potency and specificity of the DT388IL-3 molecule, we constructed variants with altered residues in the IL-3 moiety. Two of these variants, DT 388IL-3[K116W] and DT388IL-3[Δ125-133], were produced and partially purified from Escherichia coli with excellent yields. They showed enhanced binding to the human IL-3R and greater cytotoxicity to human leukemia cell lines relative to wild-type DT388IL-3. Interestingly, the results support a previously hypothesized model for interaction of the C-terminal residues of IL-3 with a hydrophobic patch on the α-subunit of IL-3R. Rational modification of the targeting domain based on structural analysis can produce a fusion toxin with increased ability to kill tumor cells. One or both of these variant fusion proteins merit further development for therapy of chemotherapy refractory AML.

Original languageEnglish (US)
Pages (from-to)277-281
Number of pages5
JournalExperimental Hematology
Volume32
Issue number3
DOIs
StatePublished - Mar 2004

Fingerprint

Interleukin-3 Receptors
Diphtheria Toxin
Interleukin-3
Leukemia
Acute Myeloid Leukemia
Treatment Failure
Primates
Catalytic Domain
Proteins
Escherichia coli
Drug Therapy
Cell Line
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Genetics
  • Hematology
  • Oncology
  • Transplantation

Cite this

Diphtheria toxin fused to variant interleukin-3 provides enhanced binding to the interleukin-3 receptor and more potent leukemia cell cytotoxicity. / Liu, Tie Fu; Urieto, Jeffrey O.; Moore, Joseph E.; Miller, Mark S.; Lowe, A. Corinne; Thorburn, Andrew; Frankel, Arthur E.

In: Experimental Hematology, Vol. 32, No. 3, 03.2004, p. 277-281.

Research output: Contribution to journalArticle

Liu, Tie Fu ; Urieto, Jeffrey O. ; Moore, Joseph E. ; Miller, Mark S. ; Lowe, A. Corinne ; Thorburn, Andrew ; Frankel, Arthur E. / Diphtheria toxin fused to variant interleukin-3 provides enhanced binding to the interleukin-3 receptor and more potent leukemia cell cytotoxicity. In: Experimental Hematology. 2004 ; Vol. 32, No. 3. pp. 277-281.
@article{a0dc1a1a7bdd4aada45b91bb1dd0254a,
title = "Diphtheria toxin fused to variant interleukin-3 provides enhanced binding to the interleukin-3 receptor and more potent leukemia cell cytotoxicity",
abstract = "Chemoresistance is a common cause of treatment failure in patients with acute myeloid leukemia (AML). We generated a diphtheria toxin (DT) fusion protein composed of the catalytic and translocation domains of DT (DT 388) fused to interleukin-3 (IL-3). IL-3 receptors (IL-3R) are overexpressed on blasts from many AML patients. DT388IL-3 showed cytotoxicity to leukemic blasts in vitro and in vivo and minimal damage to normal tissues in nonhuman primate models. However, only a fraction of patient leukemic samples were sensitive to the agent. To enhance the potency and specificity of the DT388IL-3 molecule, we constructed variants with altered residues in the IL-3 moiety. Two of these variants, DT 388IL-3[K116W] and DT388IL-3[Δ125-133], were produced and partially purified from Escherichia coli with excellent yields. They showed enhanced binding to the human IL-3R and greater cytotoxicity to human leukemia cell lines relative to wild-type DT388IL-3. Interestingly, the results support a previously hypothesized model for interaction of the C-terminal residues of IL-3 with a hydrophobic patch on the α-subunit of IL-3R. Rational modification of the targeting domain based on structural analysis can produce a fusion toxin with increased ability to kill tumor cells. One or both of these variant fusion proteins merit further development for therapy of chemotherapy refractory AML.",
author = "Liu, {Tie Fu} and Urieto, {Jeffrey O.} and Moore, {Joseph E.} and Miller, {Mark S.} and Lowe, {A. Corinne} and Andrew Thorburn and Frankel, {Arthur E.}",
year = "2004",
month = "3",
doi = "10.1016/j.exphem.2003.11.010",
language = "English (US)",
volume = "32",
pages = "277--281",
journal = "Experimental Hematology",
issn = "0301-472X",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Diphtheria toxin fused to variant interleukin-3 provides enhanced binding to the interleukin-3 receptor and more potent leukemia cell cytotoxicity

AU - Liu, Tie Fu

AU - Urieto, Jeffrey O.

AU - Moore, Joseph E.

AU - Miller, Mark S.

AU - Lowe, A. Corinne

AU - Thorburn, Andrew

AU - Frankel, Arthur E.

PY - 2004/3

Y1 - 2004/3

N2 - Chemoresistance is a common cause of treatment failure in patients with acute myeloid leukemia (AML). We generated a diphtheria toxin (DT) fusion protein composed of the catalytic and translocation domains of DT (DT 388) fused to interleukin-3 (IL-3). IL-3 receptors (IL-3R) are overexpressed on blasts from many AML patients. DT388IL-3 showed cytotoxicity to leukemic blasts in vitro and in vivo and minimal damage to normal tissues in nonhuman primate models. However, only a fraction of patient leukemic samples were sensitive to the agent. To enhance the potency and specificity of the DT388IL-3 molecule, we constructed variants with altered residues in the IL-3 moiety. Two of these variants, DT 388IL-3[K116W] and DT388IL-3[Δ125-133], were produced and partially purified from Escherichia coli with excellent yields. They showed enhanced binding to the human IL-3R and greater cytotoxicity to human leukemia cell lines relative to wild-type DT388IL-3. Interestingly, the results support a previously hypothesized model for interaction of the C-terminal residues of IL-3 with a hydrophobic patch on the α-subunit of IL-3R. Rational modification of the targeting domain based on structural analysis can produce a fusion toxin with increased ability to kill tumor cells. One or both of these variant fusion proteins merit further development for therapy of chemotherapy refractory AML.

AB - Chemoresistance is a common cause of treatment failure in patients with acute myeloid leukemia (AML). We generated a diphtheria toxin (DT) fusion protein composed of the catalytic and translocation domains of DT (DT 388) fused to interleukin-3 (IL-3). IL-3 receptors (IL-3R) are overexpressed on blasts from many AML patients. DT388IL-3 showed cytotoxicity to leukemic blasts in vitro and in vivo and minimal damage to normal tissues in nonhuman primate models. However, only a fraction of patient leukemic samples were sensitive to the agent. To enhance the potency and specificity of the DT388IL-3 molecule, we constructed variants with altered residues in the IL-3 moiety. Two of these variants, DT 388IL-3[K116W] and DT388IL-3[Δ125-133], were produced and partially purified from Escherichia coli with excellent yields. They showed enhanced binding to the human IL-3R and greater cytotoxicity to human leukemia cell lines relative to wild-type DT388IL-3. Interestingly, the results support a previously hypothesized model for interaction of the C-terminal residues of IL-3 with a hydrophobic patch on the α-subunit of IL-3R. Rational modification of the targeting domain based on structural analysis can produce a fusion toxin with increased ability to kill tumor cells. One or both of these variant fusion proteins merit further development for therapy of chemotherapy refractory AML.

UR - http://www.scopus.com/inward/record.url?scp=1542267419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542267419&partnerID=8YFLogxK

U2 - 10.1016/j.exphem.2003.11.010

DO - 10.1016/j.exphem.2003.11.010

M3 - Article

C2 - 15003313

AN - SCOPUS:1542267419

VL - 32

SP - 277

EP - 281

JO - Experimental Hematology

JF - Experimental Hematology

SN - 0301-472X

IS - 3

ER -